Vimarsana
Biggest News Aggregation in the World

Page 11 - Jonathan Chang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Chang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Chang Today - Breaking & Trending Today

NovoCure (NVCR) Q4 2023 Earnings Call Transcript - Vimarsana News

NovoCure (NVCR) Q4 2023 Earnings Call Transcript

NVCR earnings call for the period ending December 31, 2023.

Source: yahoo.com
NovoCure (NVCR) Q4 2023 Earnings Call Transcript - Vimarsana News

NovoCure (NVCR) Q4 2023 Earnings Call Transcript

NVCR earnings call for the period ending December 31, 2023.

Source: fool.com
The Money and Drugs That Tie Elon Musk to Some Tesla Directors - Vimarsana News

The Money and Drugs That Tie Elon Musk to Some Tesla Directors

Board members have reaped hundreds of millions from stock awards and separate investments, even as some have done drugs with Musk; former Tesla director Larry Ellison offered him a chance to dry out.

J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition - Vimarsana News

J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition

Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the investment bank said big pharmas are looking for deals involving de-risked assets.

After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus - Vimarsana News

After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.